Abstract:Introduction: Primary breast lymphoma (PBL) is rare, and most cases occur in female patients, with few reported cases in male patients. The clinical presentation is similar to that of breast cancer, but the condition needs to be well understood, as treatment options and clinical course vary. Hence, we provide a relatively rare case of primary breast diffuse large B cell lymphoma (PB-DLBCL) in a male, including its complete clinicopathological features, radiological findings, genomic mutational profiles, and clinical course. Case presentation: A 45-year-old male presented with a lump in his right breast for 1 week and was pathologically diagnosed with breast malignancy after a breast puncture biopsy at the local hospital. He came to our hospital for further treatment and underwent breast ultrasound and systemic positron emission tomography/computed tomography (PET/CT) imaging, followed by right mastectomy and sentinel lymph node biopsy. Histomorphology showed diffuse hyperplasia of tumor cells with clear boundaries and surrounding normal breast ducts. The adhesion of tumor cells was poor with obvious atypia. Immunohistochemical results showed that the tumor cells were positive for CD20, Bcl6, and MUM-1 but negative for CK (AE1/AE3), ER, PR, CD3, and CD10. Forty percent of the tumor cells were positive for c-Myc, and 80% of tumor cells were positive for Bcl2. The Ki-67 proliferation index was up to 80%. The tumor cells were negative for MYC and BCL2 rearrangements but positive for BCL6 rearrangement by fluorescent in situ hybridization. No abnormality was found in the pathological examination of bone marrow aspiration. Therefore, the male was diagnosed with PB-DLBCL, nongerminal center (non-GCB) phenotype, dual-expression type. The sample were sequenced by a target panel of 121 genes related to lymphoma. Next-generation sequencing revealed six tumor-specific mutated genes (IGH/BCL6, TNFAIP3, PRDM1, CREBBP, DTX1, and FOXO1). The patient was given six cycles of orelabrutinib plus R-CHOP chemotherapy and two cycles of intrathecal injection of cytarabine. The last follow-up was on April 13, 2023 (17 months). No recurrence or metastasis was found in laboratory and imaging examinations. Conclusion: We reported a relatively rare PB-DLBCL in a male, non-GBC phenotype, dual-expression type. It is worth mentioning that this case had IgH/BCL6 fusion, nonsense mutations in TNFAIP3, frameshift mutations in PRDM1, and missense mutations in CREBBP, DTX1, and FOXO1. To the best of our knowledge, this case is the first report of genomic mutational profiles of PB-DLBCL in males.

The Treatment of Diffuse Large B-Cell Lymphoma (Triple Expression) Involving the Breast, Spleen, and Bone in a Male Patient with Viral Hepatitis B: A Rare Case Report

Clinical and Histological Features of Primary Testicular Diffuse Large B-cell Lymphoma: a Single Center Experience in China

Treatment with Bortezomib in a Patient with Heavily Pretreated Refractory T‐cell Lymphoblastic Lymphoma

Effective Management of a Rare Case of Primary Renal Intravascular Large B-cell Lymphoma with Modified R-CHOP Regimen: A Case Report

Secondary Mixed Phenotype Acute Leukemia Following Chemotherapy for Diffuse Large B-cell Lymphoma: a Case Report and Review of the Literature.

A Rare Case of Systemic Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma With Hemophagocytic Lymphohistiocytosis in an Immunocompetent Young Man: Potential Diagnostic Pitfall and Therapeutic Challenge

Case Report Diffuse Large B-cell Lymphoma in the Primary Bone Marrow

Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review

“Double Hit” B-lymphoblastic Lymphoma with Concurrent IGH/BCL2 and 8q24/myc Translocations: a Case Report

Hepatitis B Virus-Associated Diffuse Large B-cell Lymphoma: Unique Clinical Features, Poor Outcome, and Hepatitis B Surface Antigen-Driven Origin.

Transition From Epstein-Barr Virus (EBV)-Positive Rectal Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma in the Lung

Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma

Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era

Experience of multi-disciplinary treatment of multiple cerebellar diffuse large B-cell lymphoma: A case report

Double-hit monomorphic B-cell lymphoma after liver transplantation

Multimodality Radiologic and Pathologic Findings in Large B-cell Lymphoma With Hepatic Presentation in an Unusually Young Male

Clinical Analysis and Prognostic Significance of Hepatitis B Virus Infections for Diffuse Large B-cell Lymphoma with or Without Rituximab Therapy

CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?

Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center

BCMA CAR-T Induces Complete and Durable Remission in Plasmablastic Lymphoma Synchronous Transformation of Chronic Lymphocytic Leukemia: Case Report and Literature Review

Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection